Drug Makers Say Japan's PMDA Drug Review Performance Improving
This article was originally published in PharmAsia News
Executive Summary
Japan's drug review body, the Pharmaceutical and Medical Device Agency, has significantly improved performance of the drug review process, demonstrated by shortened review times and higher satisfaction ratings, said the Office of Pharmaceutical Industry Research, a policy think tank under the industry trade association Japan Pharmaceutical Manufacturers Association
You may also be interested in...
Japan's Clinical Trial Costs Average ¥2 Million; Number Of Trials On The Rise
TOKYO - The number of clinical trials being performed in Japan is trending upward every year, but trial costs fluctuate sharply from year to year, according to survey results released by Japan's Pharmaceutical Manufacturers Association
Japan's Clinical Trial Costs Average ¥2 Million; Number Of Trials On The Rise
TOKYO - The number of clinical trials being performed in Japan is trending upward every year, but trial costs fluctuate sharply from year to year, according to survey results released by Japan's Pharmaceutical Manufacturers Association
As Tokyo Regulators Open More To Global Clinical Trial Data, Some Japanese Drug Outfits Move West To Expand
Leaders of the India-based Veeda Clinical Research said that by placing a bridging study leg in a clinical trial program early on time lags that often exist between regulatory agencies in the West and in Asia can be further reduced. That strategy can also expedite a drug's entry into other markets and thus benefit both patients and the pharmaceutical companies behind the new products